Research
From rare variants to individualized therapeutic pathways
Life House develops a translational research platform for rare genetic conditions associated with highly complex neurodevelopmental profiles. The aim is to connect laboratory science to the real lives of children, young people, and families.
In partnership with Professor Vladimir Katanaev and the University of Geneva, Life House supports a research workflow based on the screening of approved molecules in order to identify therapeutic candidates for rare genetic situations requiring highly individualized approaches.
In collaboration with EspeRare, N-Lorem, HUG, and international therapeutic networks, Life House also contributes to building access pathways for individualized antisense therapies. These approaches remain rare and difficult to access, particularly in Europe, and require strong scientific, clinical, and regulatory coordination.
What makes Life House distinctive is not research alone, but the link between research and life. The project is built so that scientific advances can eventually be understood, discussed, and integrated into long-term care environments rather than remaining isolated in hospital or laboratory settings.